ALERT: This system is being upgraded on Tuesday December 12. It will not be available
for use for several hours that day while the upgrade is in progress. Deposits to DukeSpace
will be disabled on Monday December 11, so no new items are to be added to the repository
while the upgrade is in progress. Everything should be back to normal by the end of
day, December 12.
Browsing by Author "Mannelli, Paolo"
Now showing items 1-20 of 34
-
Alcohol and drug use disorders among adults in emergency department settings in the United States.
(Annals of emergency medicine, 2012-08)Improving identification and treatment for substance use disorders is a national priority, but data about various drug use disorders encountered in emergency departments (EDs) are lacking. We examine past-year substance ... -
An integrated alcohol abuse and medical treatment model for patients with hepatitis C.
(Dig Dis Sci, 2012-04)BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection have high rates of alcohol consumption, which is associated with progression of fibrosis and lower response rates to HCV treatment. AIMS: This prospective ... -
Association of chronic non-cancer pain status and buprenorphine treatment retention among individuals with opioid use disorder: Results from electronic health record data.
(Drug and alcohol dependence reports, 2022-06)<h4>Background</h4>Although chronic non-cancer pain (CNCP) is common among individuals with opioid use disorder (OUD), its impact on buprenorphine treatment retention is unclear. The goal of this study was to use electronic ... -
Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network.
(Addiction (Abingdon, England), 2021-01-11)<h4>Background and aims</h4>Physician and pharmacist collaboration may help address the shortage of buprenorphine-waivered physicians and improve care for patients with opioid use disorder (OUD). This study investigated ... -
Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.
(Current drug abuse reviews, 2012-03)Constant refinement of opioid dependence (OD) therapies is a condition to promote treatment access and delivery. Among other applications, the partial opioid agonist buprenorphine has been studied to improve evidence-based ... -
Cannabis use disorders are comparatively prevalent among nonwhite racial/ethnic groups and adolescents: a national study.
(Journal of psychiatric research, 2014-03)The racial/ethnic composition of the US population is shifting, with the nonwhite population growing faster than whites. We examined cannabis use disorder (CUD) prevalences and correlates in seven racial/ethnic groups. We ... -
Clinical epidemiology of substance use disorders: Understanding patterns, sharing knowledge, planning interventions.
(The Indian journal of medical research, 2019-04) -
Commentary on Winhusen et al. (2019): Substance use disorders, chronic diseases, and electronic health records-a paradigm for screening and intervention.
(Addiction (Abingdon, England), 2019-08) -
Comorbid substance use disorders with other Axis I and II mental disorders among treatment-seeking Asian Americans, Native Hawaiians/Pacific Islanders, and mixed-race people.
(Journal of psychiatric research, 2013-12)Little is known about behavioral healthcare needs of Asian Americans (AAs), Native Hawaiians/Pacific Islanders (NHs/PIs), and mixed-race people (MRs)-the fastest growing segments of the U.S. population. We examined substance ... -
Differences in onset and abuse/dependence episodes between prescription opioids and heroin: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
(Subst Abuse Rehabil, 2011-05)OBJECTIVES: To examine patterns of onset and abuse/dependence episodes of prescription opioid (PO) and heroin use disorders in a national sample of adults, and to explore differences by gender and substance abuse treatment ... -
Early outcomes following low dose naltrexone enhancement of opioid detoxification.
(The American journal on addictions, 2009-03)Although withdrawal severity and treatment completion are the initial focus of opioid detoxification, post-detoxification outcome better defines effective interventions. Very low dose naltrexone (VLNTX) in addition to methadone ... -
Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.
(Journal of clinical psychopharmacology, 2007-10)BACKGROUND: The clinical use of naltrexone (NTX) in the treatment of opioid dependence has been limited because of poor compliance and inconsistent outcomes. In particular, the therapeutic benefit of extended treatment with ... -
Evaluating brief screeners to discriminate between drug use disorders in a sample of treatment-seeking adults.
(General hospital psychiatry, 2013-01)OBJECTIVE:The objective was to identify a potential core set of brief screeners for the detection of individuals with a substance use disorder (SUD) in medical settings. METHOD:Data were from two multisite studies that evaluated ... -
Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
(Drug and alcohol dependence, 2014-05)The approval of extended release injectable naltrexone (XR-NTX; Vivitrol(®)) has introduced a new option for treating opioid addiction, but studies are needed to identify its place within the spectrum of available therapies. ... -
Family substance use screening: less to hide, more to gain.
(Indian J Med Res, 2016-06) -
Hallucinogen use disorders among adult users of MDMA and other hallucinogens.
(The American journal on addictions, 2008-09)We investigated the prevalence, patterns, and correlates of past-year DSM-IV hallucinogen use disorders (HUDs) among past-year users of MDMA and other hallucinogens from a sample of Americans 18 or older (n = 37,227). Users ... -
Opioid use disorder deaths and the effects of medication therapy.
(The American journal of drug and alcohol abuse, 2019-01) -
Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S.
(Addiction science & clinical practice, 2023-08)<h4>Background</h4>Pharmacy administration and dispensing of methadone treatment for opioid use disorder (PADMOUD) may address inadequate capability of opioid treatment programs (OTPs) in the US by expanding access to methadone ... -
Pharmacological enhancement of naltrexone treatment for opioid dependence: a review.
(Subst Abuse Rehabil, 2011-06)PURPOSE: Opioid dependence (OD) is a serious and growing clinical condition with increasing social costs that requires expanding treatment beyond opioid agonist substitution. The opioid antagonist naltrexone has displayed ... -
Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff.
(Substance abuse treatment, prevention, and policy, 2023-09)<h4>Background</h4>The US federal regulations allow pharmacy administration and dispensing of methadone for opioid use disorder (PADMOUD) to increase the capability of opioid treatment programs (OTPs) in providing methadone ...
